Navigation Links
Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Date:9/10/2007

well as statements regarding the Company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the Company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect," "anticipate," "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases are intended to identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: the value and use of data to be produced in the Phase 1 trial; the timing of announcing data from the Phase 1 trial; the launching of a Phase 2 clinical trial in CIN patients; the possibility of a second Phase 2 trial in HIV-positive CIN patients; the design of the Phase 1 trial; and the collection and use of immunological data to indicate efficacy of the compound.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our need for capital, risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug be found safe and effective after extensive clinical trials and the possibility that the results
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
2. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
3. Easy preparation of total RNA from cultured cells with TRIzol and Eppendorf Phase Lock Gel
4. Identification of cells in S phase using the Cell Proliferation Fluorescence Kit and IN Cell Analyzer 1000
5. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
6. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
7. Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System
8. Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System
9. ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION
10. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
11. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... ... of their entire waste to energy process and continue to contribute to the ... Upgrade , Temarry’s Waste to Energy process has been operating at their Mexico ...
(Date:9/2/2015)... ... September 02, 2015 , ... Genedata, a leading ... unveiled Genedata Screener ® version 13.0 at ELRIG Drug Discovery 2015. This ... a rich set of new capabilities. Screener now supports High Throughput Flow Cytometry ...
(Date:9/1/2015)... Carolina (PRWEB) , ... September 02, 2015 , ... ... released new features to its eCommerce site Spirax Sarco Anytime. This platform, offering ... Why wait to place your next order? Log on to Spirax Sarco Anytime ...
(Date:9/1/2015)... EDISON, N.J. , Sept. 1, 2015  ContraVir ... focused on the development and commercialization of targeted antiviral ... Rodman & Renshaw 17 th Annual Global Investment ... taking place September 8-10, 2015 at The St. Regis ... James Sapirstein , Chief Executive ...
Breaking Biology Technology:Temarry Recycling’s New $100,000 Waste to Energy Renovation 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4Spirax Sarco Announces New Features to Anytime Platform 2ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... TORONTO, Aug. 27 Drug Royalty LP 2 ... Pharmaceuticals, Inc.,s (ENZN) worldwide,royalty interest in PEG-INTRON for ... in 2012 should certain royalty recognition levels be ... of,Hepatitis C and is marketed worldwide by Schering-Plough ...
... Notice is hereby,given that the 2007 Annual General Meeting ... (NASDQ:ROSG) (the "Company"), an,Israeli company, will be held at ... Tower, 47th floor, Tel Aviv, Israel on Monday, September ... purposes: 1. To approve the appointment of Kost, ...
... SAN CARLOS, Calif., Aug. 27 NeurogesX, Inc.,(Nasdaq: NGSX ... announced today that it is scheduled to present,at the 2007 ... Anthony DiTonno, President and Chief Executive Officer,and Stephen Ghiglieri, Chief ... Date: Thursday, September 6, 2007 ...
Cached Biology Technology:Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN) 2Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007 2NeurogesX to Present at BioCentury's NewsMakers in the Biotech Industry Conference 2NeurogesX to Present at BioCentury's NewsMakers in the Biotech Industry Conference 3
(Date:8/6/2015)... 6, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced collaboration with Microsoft on biometric ... Microsoft leveraged Synaptics, deep expertise in human interface ... Through stringent testing, Synaptics, advanced image ... Microsoft,s Precision TouchPad (PTP) specification empowering OEMs with ...
(Date:8/4/2015)... 4, 2015  AMRI (NASDAQ: AMRI ) today reported financial ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 ... including a $0.05 decrease in EPS from royalties in the current ... "We are very pleased to present another strong ...
(Date:7/31/2015)... La 10e Conférence internationale sur la ... le BGI du 22 au 25 octobre 2015 ... La conférence célèbre son 10e anniversaire ... est devenue l,une des réunions annuelles mondiales les ... c,est aussi la plus dynamique, la plus enthousiaste ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... digital certificates help secure new biometrics to be stored on ... ... and global security,threats, coupled with rapidly emerging standards and technology, ... more,sophisticated machine readable travel documents (MRTDs) to their citizens.,Entrust, Inc. ...
... tell you a lot about the past, but you ... appearing this month in Genome Research reveals that protein ... proteins provide an extraordinary window on the history ... University of Illinois describe contemporary protein architectures as molecular ...
... SPRING HARBOR, N.Y. (Mon., Oct. 1, 2007) Research ... provide knowledge about biological mechanisms that underlie our ability ... To facilitate such research, two neuroscience methods are featured ... Protocols . Both are freely accessible online ( www.cshprotocols.org ...
Cached Biology News:Entrust Continues Leadership by Adding Support for Next-generation E-Passports 2Entrust Continues Leadership by Adding Support for Next-generation E-Passports 3Census of protein architectures offers new view of history of life 2Census of protein architectures offers new view of history of life 3Census of protein architectures offers new view of history of life 4From brains to behavior: Cold Spring Harbor Protocols features methods for neuroscience research 2